Porter, Ross J.
Murray, Graeme I.
Brice, Daniel P.
Petty, Russell D.
McLean, Mairi H.
Article History
Received: 17 March 2019
Revised: 30 October 2019
Accepted: 28 November 2019
First Online: 13 December 2019
Ethics approval and consent to participate
: Ethical approval for use of human tissue including the tissue microarray in this study was obtained from the Scientific Access Committee of the Grampian Tissue Biorepository (Tissue Request No.53 & 118). The Biorepository has delegated research ethics authority (11/NS/0015) from The North of Scotland research ethics committee to approve research projects involving human tissue and data. All tissue and data were anonymised. Project specific written consent was not required for the retrospective use of archival tissue. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: All data is published within this paper and within accompanying supporting files (indicated in text) and accessed via weblink on the journal site.
: R.D.P. has received honoraria from Bristol-Myers Squibb and Roche for advisory roles and from Pfizer for lectures on precision cancer medicine. R.D.P. has also received grants for clinical research from Bristol-Myers Squibb, AstraZeneca, Merck Serono, Merck & Co, Five Prime Therapeutics, and ARMO Biosciences (this research involves immunotherapies in gastric and oesophageal cancer and is not related to the research in this paper). The remaining authors report no competing interests.
: The preparation of this paper was funded in part by the Pathological Society of Great Britain and Ireland (intercalated degree educational studentship to R.J.P.).